Comparison · NCT00774852-4f7eef2d
Abatacept vs Placebo: Number of Participants With Partial Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. Abatacept vs Placebo: Number of Participants With Partial Response. Trial comparisons, record NCT00774852-4f7eef2d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00774852-4f7eef2d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.591 | 0.47 | 0.701 | wilson | |
| Risk in group 2 | 0.588 | 0.47 | 0.697 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00267 | -0.16 | 0.165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.757 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.508 | 2.01 | log | |
| Number needed to treat, for one more participant with the outcome on Abatacept than on Placebo | 374 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abatacept | Subjects received abatacept IV dosed according to body weight (\<60 kg, 500mg; 60-100 kg, 750 mg; or \>100 kg, 1 g) at the following visits: Weeks (wks) 0, 2, and 4, then every 4 wks until Wk 24. Subjects also received: 1) cyclophosphamide 500 mg IV every 2 wks for 6 doses followed by azathioprine 2 mg/kg/day by mouth dosed by body weight at Visit 6 (rounded to the nearest 25 mg and to a maximum dose of 200 mg) for 16 wks; 2) prednisone 60 mg/day for the first 2 wks (subjects less than 60 kg could receive 1 mg/kg/day).\* Prednisone was tapered until Wk 12 to a dose of 10 mg/day. This dose was continued until Wk 24 unless the subject had a prednisone-related toxicity requiring further reduction.\* After Wk 24, prednisone was permitted to be tapered further to 5mg/day.\* Subjects who achieved a complete response discontinued abatacept and switched to azathioprine placebo up to Wk 52 (to assess response durability). \*Based on principal investigator \[PI\] judgment. | 39 | 66 | OG000 |
| Group 2 | Placebo | Subjects received abatacept placebo IV at the following visits: Weeks (wks) 0, 2 and 4, then every 4 wks until Wk 24. Subjects also received: 1) cyclophosphamide 500 mg IV every 2 wks for 6 doses followed by azathioprine 2 mg/kg/day by mouth dosed according to body weight at Visit 6 (rounded to the nearest 25 mg and to a maximum dose of 200 mg) for 16 wks; 2) prednisone 60 mg/day for the first two wks (subjects less than 60 kg could receive 1 mg/kg/day.\*Prednisone was tapered until Wk 12 to a dose of 10 mg/day. This dose was continued until Wk 24 unless the subject had a prednisone-related toxicity that required further reduction.\* After Wk 24, prednisone was permitted to be tapered further to 5mg/day.\* Subjects who achieved a complete response discontinued abatacept placebo and continued azathioprine up to Wk 52. \*Based on principal investigator \[PI\] judgment. | 40 | 68 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Partial Response
- Description
Outcome measure description: Partial response definition: a serum creatinine \<= 1.2 mg/dL or \<= to 125% of the higher value at either screening or baseline visit, and improvement (reduction) \>= to 50% in the urine protein to creatinine ratio at either screening or baseline visit, and prednisone dose has been tapered to 10 mg/day or according to protocol dosing allowances in protocol. Participants who discontinued treatment and/or terminated from the study in the first 24 weeks were defined as complete response failures for all subsequent visits. Partial responders are those who showed some response to treatment and low activity of their lupus nephritis.
- Time frame
- Week 24
- Population
- Intent-to-treat
Source ClinicalTrials.gov
Trial
- Title
- Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
- NCT number
- NCT00774852
- Phases
- PHASE2
- Conditions
- Lupus Nephritis, Lupus Erythematosus, Systemic
- Interventions
- abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2014-10-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00774852?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00774852-4f7eef2d